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Abstract This report describes the pathologic findings
for a patient with Hunter syndrome who underwent aortic
valve replacement at 10 years of age, 3 years after the
initiation of enzyme replacement therapy. Aortic valve
pathology showed mild thickening and fibrosis as well as
massive glycosaminoglycan accumulation. This suggests
that enzyme replacement therapy has limited efficacy for
cardiac valve disease both clinically and pathologically.
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Hunter syndrome, mucopolysaccharidosis type 2, is an
X-linked lysosomal storage disorder caused by an iduronate-
2-sulfatase deficiency. The accumulation of glycosamino-
glycans (GAGs) causes progressive systemic organ failure.
Major mortality factors are central nervous system involve-
ment, cardiac involvement, and upper airway obstruction.
Death in the first or second decade of life is common among
severely affected patients [8].
Enzyme replacement therapy (ERT) with recombinant
human iduronate-2-sulfatase (idursulfase) improves clinical
manifestations, such as dyspnea and abnormal gait, by
reducing the accumulation of GAGs in lysosomes [5, 6].
Because almost all patients with Hunter syndrome experi-
ence the development of cardiac abnormalities, cardiac
evaluations, including 12-lead electrocardiography and
echocardiography, are recommended every 1–3 years
[7, 9].
However, it still is unknown whether ERT actually can
ameliorate or prevent cardiac valve disease in Hunter
syndrome. We report a patient with Hunter syndrome
receiving ERT who underwent aortic valve replacement
surgery.
Case Report
A 3-year-old boy was referred for progressive neurologic
deterioration. Hunter syndrome was confirmed by a defi-
ciency of iduronate-2-sulfatase enzyme activity. Annual
cardiac follow-up assessment, including electrocardiogra-
phy and echocardiography, was performed, and the boy
was found to have aortic regurgitation (AR) at the age of
5 years.
When the boy was 7 years old, ERT with idursulfase
(Elaprase) was initiated, but immunoglobulin-G (IgG)
antibody developed during ERT. The antibody titer
was negative at the initiation of ERT, then found to be
1:80 at 15 months, 1:800 at 20 months, and 1:1,600, at
24 months after the initiation of ERT. Aortic regurgitation
and left ventricular (LV) dysfunction progressed despite
the ERT. Cardiac catheterization and angiography showed
an increase in LV end-diastolic volume and a progression
of AR.
The patient underwent aortic valve replacement (AVR)
3 years after the initiation of ERT. A 17-mm Regent
prosthetic aortic valve (St. Jude Medical Inc., St. Paul, MN,
USA) was implanted. The aortic valve was sent to the
pathology department for analysis. Throughout surgery for
AVR, ERT was continued, even during the perioperative
period.
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Hematoxylin and eosin (H&E) staining showed mild
thickening and interstitial fibrosis of the aortic valve. We
also observed vacuolated histiocyte infiltration, otherwise
known as ‘‘clear’’ cells. Toluidine blue staining of the
aortic valve demonstrated cellular accumulation of GAGs
(Fig. 1).
Electron microscopy examination of the aortic valve
showed GAG-laden cells, similar to the general pathology
finding. In addition, we observed zebra body formation,
which indicated glycolipid accumulation (Fig. 2).
The patient continued to receive ERT 2 years after
surgery and was asymptomatic. Follow-up cardiac echo-
cardiography showed a remarkable improvement in AR
and LV function.
Discussion
Hunter syndrome manifests with progressive systemic
organ failure due to GAG accumulation caused by the lack
of iduronate-2-sulfatease. Muenzer et al. [5, 6] showed that
ERT is associated with a reduction in urine GAG levels and
organ size, as well as with an increased 6-min walk test
distance.
Cardiac involvement is common in patients with Hunter
syndrome. Wraith et al. [8] reported that 57 % of patients with
Hunter syndrome have cardiac valve disease. Mitral and
aortic valves are more likely to be affected than right-sided
Fig. 1 General pathology of the aortic valve. Toluidine blue stain
shows lysosomal accumulation of glycosaminoglycans
Fig. 2 Electron microscopy
of the aortic valve. a Arrow
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heart valves. Some reports have shown that patients with
Hunter syndrome require regular follow-up assessment, such
as electrocardiography and cardiac echocardiography, every
1–3 years [7, 9].
Before the development of ERT, some surgical cases of
mucopolysaccharidosis were reported for valve replace-
ment surgery. Bhattacharya et al. [2] and Antoniou et al.
[1] reported mitral valve replacement surgery for mitral
stenosis secondary to Hunter syndrome. Both patients in
these previous reports were adults who had never received
ERT.
Cardiac pathology of mucopolysaccharidosis has been
studied more in type 1 than in type 2. Mucopolysacchari-
dosis type 1 cardiac valve pathology characteristically shows
increased GAG content as well as infiltration of ‘‘clear’’ cells
(Hurler cells) [3]. The reported patient had the pathologic
finding of mucopolysaccharidosis type 2, similar to type 1,
in the aortic valve. It has been suggested that Hurler syn-
drome and Hunter syndrome have a similar pathophysiology
of cardiac valve disease.
Fesslova et al. [4] showed progression of cardiac valve
disease in a patient with mucopolysaccharidosis types 1
and 2. In their study of eight patients who had cardiac valve
disease and were receiving ERT, four patients had pro-
gressive disease, and the remaining four patients had stable
disease.
For the reported patient, ERT was initiated after AR had
already developed. Regardless of the ERT, cardiac valve
disease deteriorated, and finally, AVR was performed. The
finding of GAG accumulation in the aortic valve of the
reported patient suggests that ERT does not reverse cardiac
valve disease in Hunter syndrome. Therefore, ERT might
not be effective after the onset of cardiac valve disease.
Valve replacement surgery for a patient with Hunter syn-
drome during ERT has not been previously reported.
The actual mechanism of cardiac disease in mucopoly-
saccharidosis remains unknown. The heparin-, dermatan-,
chondroitin-, and keratin-sulfate GAGs are normal com-
ponents of cardiac valves. Accumulation of GAG is the
main pathology of cardiac involvement in mucopolysac-
charidosis, resulting in hemodynamic decongements [3].
We report, for the first time, AVR surgery for a patient
with Hunter syndrome during ERT. In the reported patient,
although mild cardiac valve disease had developed at the
initiation of ERT, it was refractory to a 3-year course of
ERT. This suggests that ERT has a limited efficacy for
cardiac valve disease both clinically and pathologically.
Antibody formation could hinder the effects of ERT. We
hypothesize that idursulfase does not reach the cardiac
valve because of its poor vascularity. Further study is
required to determine the accurate pathophysiology of
cardiac valve disease in patients with Hunter syndrome.
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